Trial Profile
A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary) ; Cisplatin; Fluorouracil; Paclitaxel
- Indications Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ORIENT-15
- Sponsors Innovent Biologics
- 22 Oct 2023 Status changed from recruiting to completed.
- 12 Oct 2023 This trial has been discontinued in Hungary according to European Clinical Trials Database record.
- 22 Aug 2023 This trial has been discontinued in France according to European Clinical Trials Database record.